Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers

Reuters

08/20

<a href="https://laohu8.com/S/TIVC">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers

Tivic Health Systems Inc. has announced the receipt of two investigational new drug $(IND.AU)$ applications for their lead candidate, Entolimod™, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome $(ARS.UK)$ and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560105142"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560105142\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560105142?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560105142","market":"us","top_or_hot":-1,"title":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> applications for their lead candidate, Entolimod™, from <a href=\"https://laohu8.com/S/STAB\">Statera Biopharma</a>. These INDs are aimed at the treatment of acute radiation syndrome <a href=\"https://laohu8.com/S/ARS.UK\">$(ARS.UK)$</a> and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-20 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> applications for their lead candidate, Entolimod™, from <a href=\"https://laohu8.com/S/STAB\">Statera Biopharma</a>. These INDs are aimed at the treatment of acute radiation syndrome <a href=\"https://laohu8.com/S/ARS.UK\">$(ARS.UK)$</a> and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIVC","symbol_name":"Tivic Health Systems, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL4HZTRK:1","article_id":"2560105142","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560105142","pubTimestamp":1755693066,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod to Treat Acute Radiation Syndrome and Advanced Cancers. Tivic Health Systems Inc. has announced the receipt of two investigational new drug  applications for their lead candidate, Entolimod, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome  and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIVC":"Tivic Health Systems, Inc.","BK4139":"生物科技","BK4082":"医疗保健设备","STAB":"Statera Biopharma Inc"},"translate_title":"Tivic Health获得FDA批准两项恩托莫德研究性新药申请™治疗急性放射综合征和晚期癌症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAB":0.9,"TIVC":0.9},"content_text":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    \n\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug $(IND.AU)$ applications for their lead candidate, Entolimod™, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome $(ARS.UK)$ and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}